Beacon Biosignals的动态

“Neuroscience...stands out as a therapeutic area that greatly benefits from the incorporation of wearables due to the limitations of current subjective and infrequent endpoints and biomarkers... This creates a strong need to gather more objective data to support better-informed clinical decisions. Furthermore, the shift from merely treating symptoms to implementing disease-modifying approaches demands a precision and understanding that current clinical or cognitive biomarkers simply cannot provide.” In a recent Clinical Tech Leader interview, Bryan J. Hansen, Ph.D., Director of Innovative Health at Johnson & Johnson Innovative Medicine, discusses why scalability, reduced participant burden, real-world insights, and clinically rigorous, objective data make wearables, particularly sleep measurement, essential for decentralized neuroscience trials. Read the full interview here: https://lnkd.in/ejhSWrN6 #Neuroscience #Wearables #DecentralizedTrials #CNSDrugDevelopment